Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IGVTS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CD74 ADC 16-5
|
|||||
| Synonyms |
Anti-CD74-ADC 16-5
Click to Show/Hide
|
|||||
| Organization |
Merck & Co., Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Diffuse large B-cell lymphoma [ICD11:2A81]
Investigative
Renal cell carcinoma [ICD11:2C90]
Investigative
Sezary syndrome [ICD11:2B02]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-hCD74 LL1
|
Antibody Info | ||||
| Antigen Name |
HLA class II histocompatibility antigen gamma chain (CD74)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Anti-CD74 ADC 16-5 linker
|
|||||
| Conjugate Type |
The drug linker was conjugated to the unnatural amino acid (UAA) para-azido phenylalanine (p-AF)
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.